Check 35,000+ stocks against 26 valuation models and 37 quality factors

Neuroone Medical Technologies Corp (NMTC) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Neuroone Medical Technologies Corp $0.64, price $1.34, upside -52.4%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · ISIN US64130M2098

Thin data Sep 23, 2026

Neuroone Medical Technologies Corp

NMTC · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.6375 · Strongly overvalued (−52%)

!Quality 48/100

!Mixed Growth (revenue 5y +44.4 %/yr)

!Loss-making · -52.2% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (2/10)

!Narrow moat 10/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.4165 to bull $0.7990 Growth analysisrevenue history, year by year Quality 48/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Neuroone Medical Technologies Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $1.30 – $40.92 · fair‑value band $0.4165 – $0.7990 · the $1.34 price screens above the $0.6375 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Neuroone Medical Technologies in your weekly email

Every Wednesday you see whether Neuroone Medical Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

Stock analysis

Neuroone Medical Technologies Corp (NMTC) currently trades at $1.34, while our model-based Fair Value estimate is $0.6375, implying the stock looks roughly 110.2% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.4165 (bear) to $0.7990 (bull), the price of $1.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Neuroone Medical Technologies Corp reported revenue of $12.1M in FY2025 versus $178K in FY2021, a compound +187.1%/yr. Reported net income was −$3.6M in FY2025.

Key figures

Market cap $28.6M · P/S ratio 2.25 · EPS (TTM) $−0.8900 · Net margin −29.8% · Return on equity −204% · Return on assets (EBIT) −123% · Operating margin −87.9% · Revenue (TTM) $12.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −52%, NMTC screens richer than that median.

Fair Value models

Bear $0.4165 Fair Value $0.6375 Bull $0.7990

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.4100 $0.5400 $0.8100 54

All 1 models by family

Asset-Based

NCAV (Graham) $0.4100 $0.5400 $0.8100 54

Open the full fair value analysis →

Notify me when NMTC reaches fair value

Put NMTC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 49 · Market factors (momentum, volatility) 15

Profitability 37

Margins and returns on capital today

Quality Growth 100

Are margins and returns improving?

Cashflow 6

Earnings quality: real cash, not paper profit

Fin. Strength 73

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 0

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+250.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+313.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+44.4%

Start year 2020 (pandemic). Over 10 years: +162.7% a year

Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+85.2%

’11

’12

’13

’14

’15

’16

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−254.5% (2020) → −34.9% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

NMTC screens 110% overvalued. Compare with Abbott Laboratories, →

Compare Neuroone Medical Technologies Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 49 · Below median

Fair Value upside −52% · Below median

Profitability

Return on assets −72% · Bottom 25%

Net margin (TTM) −52% · Bottom 25%

Operating margin (TTM) −88% · Bottom 25%

Growth and dividend

Revenue growth 73% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.05× · Priciest 25%

P/S (TTM) 2.25× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 10

FUTURE (revenue growth)100 · sector 31

PAST (return on equity)0 · sector 7

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$103.49	$74.79	−28%
Stryker Corporation SYK	$273.40	$300.74	+10%
Medtronic plc MDT	$89.30	$65.57	−27%
Boston Scientific Corporation BSX	$44.62	$49.08	+10%
Edwards Lifesciences Corporation EW	$86.82	$82.04	−6%
Siemens Healthineers AG SHL	€37.21	€35.22	−5%
DexCom, Inc DXCM	$87.73	$96.50	+10%
GE HealthCare Technologies Inc GEHC	$66.27	$69.62	+5%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥156.68	¥172.35	+10%
Koninklijke Philips N.V PHIA	€21.85	€15.32	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neuroone Medical Technologies Corp · Fair Value
$0.6375 −110%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/NMTC" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Neuroone Medical Technologies Corp · Fair Value</span><br><b style="font-size:20px">$0.6375</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−110%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Neuroone Medical Technologies Corp Fair Value". https://www.fairvalue-calculator.com/stock/NMTC

Frequently asked questions

Is Neuroone Medical Technologies Corp (NMTC) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $0.6375 versus a price of $1.34, about −52% upside (overvalued).

What is the fair value of NMTC?

Our model-based fair value for Neuroone Medical Technologies Corp is $0.6375 (as of Sep 23, 2026), built from audited fundamentals. The current price: $1.34.

What is the quality score of NMTC?

Neuroone Medical Technologies Corp has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Neuroone Medical Technologies Corp (NMTC)?

Our model-based price target is the fair value of $0.6375 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.4165, optimistic scenario $0.7990. It is a calculation from audited fundamentals, not an analyst target.

What is the Neuroone Medical Technologies Corp stock forecast for 2026?

Our models put fair value at $0.6375, about −52% upside versus a price of $1.34 (overvalued). Cautious scenario $0.4165, optimistic scenario $0.7990. The calculation is refreshed regularly with new filings.

What is the revenue of Neuroone Medical Technologies Corp (NMTC)?

Neuroone Medical Technologies Corp reported trailing-twelve-month revenue of about $12.7M (latest available figure, as of Sep 23, 2026).

What is the intrinsic value of Neuroone Medical Technologies Corp (NMTC)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuroone Medical Technologies Corp it is $0.6375 per share (as of Sep 23, 2026), against a price of $1.34. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Neuroone Medical Technologies Corp stock overvalued or undervalued in 2026?

As of Sep 23, 2026, NMTC trades above its calculated fair value: price $1.34, fair value $0.6375, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of NMTC?

No. The price is what the market pays today ($1.34); the fair value is what the company's own numbers justify ($0.6375). For Neuroone Medical Technologies Corp the two are $0.7025 per share apart. That gap is exactly why we show both numbers side by side.

How much is Neuroone Medical Technologies Corp worth?

The market values Neuroone Medical Technologies Corp at about $28.6M (market capitalisation, as of Sep 23, 2026). Per share that is $1.34; our models calculate a fair value of $0.6375 per share.

What do the bullish and bearish scenarios say about NMTC?

Our models span a range for Neuroone Medical Technologies Corp: cautious scenario $0.4165, base $0.6375, optimistic $0.7990 per share (as of Sep 23, 2026, price $1.34). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Neuroone Medical Technologies Corp (NMTC)?

Balance-sheet figures for Neuroone Medical Technologies Corp (as of Sep 23, 2026): return on equity −204.4%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.

How far is NMTC from its 52-week high?

Neuroone Medical Technologies Corp trades at $1.34, about 79% below its 52-week high of $6.36 and 3% above the low of $1.30 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6375 is for.

Which stocks are comparable to Neuroone Medical Technologies Corp?

From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Neuroone Medical Technologies Corp stock attractive at the current price?

The data as of Sep 23, 2026: price $1.34, calculated fair value $0.6375 (−52%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of NMTC calculated?

We run Neuroone Medical Technologies Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6375, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.0 % above its aggregate fair value. Neuroone Medical Technologies Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Neuroone Medical Technologies Corp (NMTC)?

The closing price on Sep 23, 2026 was $1.34. Our model-based fair value is $0.6375, about −52% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Neuroone Medical Technologies Corp right now?

The price sits above even our optimistic bull case ($0.7990). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.4165 to $0.7990) leaves room in how you read the outcome.

Key figures of Neuroone Medical Technologies Corp

How large is the market capitalisation of Neuroone Medical Technologies Corp (NMTC)?

The market capitalisation of Neuroone Medical Technologies Corp is $28.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Neuroone Medical Technologies Corp (NMTC)?

The price-to-sales ratio of Neuroone Medical Technologies Corp is 2.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Neuroone Medical Technologies Corp (NMTC)?

Earnings per share at Neuroone Medical Technologies Corp are $−0.8900. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Neuroone Medical Technologies Corp (NMTC)?

The net margin of Neuroone Medical Technologies Corp is −29.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Neuroone Medical Technologies Corp (NMTC)?

The return on equity (ROE) of Neuroone Medical Technologies Corp is −204% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Neuroone Medical Technologies Corp (NMTC)?

On an EBIT basis the return on assets of Neuroone Medical Technologies Corp is −123% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Neuroone Medical Technologies Corp (NMTC)?

The operating margin of Neuroone Medical Technologies Corp is −87.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Neuroone Medical Technologies Corp (NMTC)?

Revenue at Neuroone Medical Technologies Corp is growing +72.5% versus a year earlier (3y avg +313%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Neuroone Medical Technologies Corp (NMTC) generate?

The free cash flow of Neuroone Medical Technologies Corp is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Neuroone Medical Technologies Corp (NMTC) hold?

Neuroone Medical Technologies Corp holds more cash than debt, $6.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Neuroone Medical Technologies Corp in the live analysis

One click puts Neuroone Medical Technologies Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.